PRAXIS PRECISION MEDICINES I (PRAX) Stock Fundamental Analysis

NASDAQ:PRAX • US74006W2070

335.28 USD
+3.67 (+1.11%)
At close: Feb 20, 2026
335.28 USD
0 (0%)
After Hours: 2/20/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to PRAX. PRAX was compared to 520 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for PRAX as it has an excellent financial health rating, but there are worries on the profitability. PRAX is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PRAX has reported negative net income.
  • PRAX had a negative operating cash flow in the past year.
  • PRAX had negative earnings in each of the past 5 years.
  • In the past 5 years PRAX always reported negative operating cash flow.
PRAX Yearly Net Income VS EBIT VS OCF VS FCFPRAX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • With a Return On Assets value of -68.88%, PRAX is not doing good in the industry: 62.00% of the companies in the same industry are doing better.
  • The Return On Equity of PRAX (-79.49%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -68.88%
ROE -79.49%
ROIC N/A
ROA(3y)-121.32%
ROA(5y)-88.85%
ROE(3y)-166.41%
ROE(5y)-118.06%
ROIC(3y)N/A
ROIC(5y)N/A
PRAX Yearly ROA, ROE, ROICPRAX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

1.3 Margins

  • PRAX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRAX Yearly Profit, Operating, Gross MarginsPRAX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • PRAX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
PRAX Yearly Shares OutstandingPRAX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
PRAX Yearly Total Debt VS Total AssetsPRAX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

  • An Altman-Z score of 97.66 indicates that PRAX is not in any danger for bankruptcy at the moment.
  • PRAX's Altman-Z score of 97.66 is amongst the best of the industry. PRAX outperforms 99.23% of its industry peers.
  • There is no outstanding debt for PRAX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 97.66
ROIC/WACCN/A
WACC8.72%
PRAX Yearly LT Debt VS Equity VS FCFPRAX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

  • PRAX has a Current Ratio of 5.18. This indicates that PRAX is financially healthy and has no problem in meeting its short term obligations.
  • PRAX has a Current ratio (5.18) which is in line with its industry peers.
  • A Quick Ratio of 5.18 indicates that PRAX has no problem at all paying its short term obligations.
  • PRAX has a Quick ratio (5.18) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 5.18
Quick Ratio 5.18
PRAX Yearly Current Assets VS Current LiabilitesPRAX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • PRAX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -31.06%.
EPS 1Y (TTM)-31.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

  • Based on estimates for the next years, PRAX will show a very strong growth in Earnings Per Share. The EPS will grow by 50.15% on average per year.
  • The Revenue is expected to grow by 868.35% on average over the next years. This is a very strong growth
EPS Next Y0.6%
EPS Next 2Y13.76%
EPS Next 3Y34.08%
EPS Next 5Y50.15%
Revenue Next Year38343.6%
Revenue Next 2Y8536.45%
Revenue Next 3Y2488.83%
Revenue Next 5Y868.35%

3.3 Evolution

PRAX Yearly Revenue VS EstimatesPRAX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B
PRAX Yearly EPS VS EstimatesPRAX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 50 -50 100

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • PRAX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year PRAX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRAX Price Earnings VS Forward Price EarningsPRAX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRAX Per share dataPRAX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

  • PRAX's earnings are expected to grow with 34.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y13.76%
EPS Next 3Y34.08%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • PRAX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PRAXIS PRECISION MEDICINES I

NASDAQ:PRAX (2/20/2026, 8:00:01 PM)

After market: 335.28 0 (0%)

335.28

+3.67 (+1.11%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-30
Inst Owners89.85%
Inst Owner Change4.22%
Ins Owners0.22%
Ins Owner Change1.82%
Market Cap9.19B
Revenue(TTM)N/A
Net Income(TTM)-273.04M
Analysts82.86
Price Target597.99 (78.36%)
Short Float %15.06%
Short Ratio5.83
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.44%
Min EPS beat(2)2.57%
Max EPS beat(2)4.3%
EPS beat(4)2
Avg EPS beat(4)1.21%
Min EPS beat(4)-1.25%
Max EPS beat(4)4.3%
EPS beat(8)4
Avg EPS beat(8)-3.68%
EPS beat(12)7
Avg EPS beat(12)4.13%
EPS beat(16)8
Avg EPS beat(16)0.77%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)409.39%
Min Revenue beat(4)-100%
Max Revenue beat(4)1937.56%
Revenue beat(8)3
Avg Revenue beat(8)301.93%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)45.67%
PT rev (3m)131.2%
EPS NQ rev (1m)-0.19%
EPS NQ rev (3m)3.88%
EPS NY rev (1m)0.14%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)-7.13%
Revenue NQ rev (3m)-7.13%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-49.35%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1231.41
P/FCF N/A
P/OCF N/A
P/B 26.75
P/tB 26.75
EV/EBITDA N/A
EPS(TTM)-13.46
EYN/A
EPS(NY)-13.38
Fwd EYN/A
FCF(TTM)-8.35
FCFYN/A
OCF(TTM)-8.35
OCFYN/A
SpS0.27
BVpS12.53
TBVpS12.53
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -68.88%
ROE -79.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-121.32%
ROA(5y)-88.85%
ROE(3y)-166.41%
ROE(5y)-118.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.02
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.18
Quick Ratio 5.18
Altman-Z 97.66
F-Score4
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)38.78%
Cap/Depr(5y)139.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-19.05%
EPS Next Y0.6%
EPS Next 2Y13.76%
EPS Next 3Y34.08%
EPS Next 5Y50.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year38343.6%
Revenue Next 2Y8536.45%
Revenue Next 3Y2488.83%
Revenue Next 5Y868.35%
EBIT growth 1Y-78.71%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.53%
EBIT Next 3Y-23.54%
EBIT Next 5Y28.37%
FCF growth 1Y-97.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-97.16%
OCF growth 3YN/A
OCF growth 5YN/A

PRAXIS PRECISION MEDICINES I / PRAX FAQ

What is the ChartMill fundamental rating of PRAXIS PRECISION MEDICINES I (PRAX) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PRAX.


What is the valuation status of PRAXIS PRECISION MEDICINES I (PRAX) stock?

ChartMill assigns a valuation rating of 1 / 10 to PRAXIS PRECISION MEDICINES I (PRAX). This can be considered as Overvalued.


What is the profitability of PRAX stock?

PRAXIS PRECISION MEDICINES I (PRAX) has a profitability rating of 0 / 10.


Can you provide the expected EPS growth for PRAX stock?

The Earnings per Share (EPS) of PRAXIS PRECISION MEDICINES I (PRAX) is expected to grow by 0.6% in the next year.